Alzheimer's Assocation Research only
All of alz.org
  • Go to Alz.org
  • Research Center
  • AAIC
  • ISTAART
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Home
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2005


To view an abstract, select an author from the vertical list on the left side.

2005 Grant - Holtzman

Effects of Neurotransmitters and Synaptic Activity on Brain ISF Beta-Amyloid

David M. Holtzman, M.D.
Washington University
St. Louis, Missouri

2005 Zenith Fellows Award

In the Alzheimer's disease brain, beta-amyloid protein fragments aggregate, or clump together, outside cells. A large body of evidence suggests that some aggregated forms of beta-amyloid have a toxic effect that disrupts cell-to-cell communication and damages cells. Recent studies have also shown that neurons may normally produce and release beta-amyloid and that levels of beta-amyloid accumulation are moderated by neural activity, or how frequently nerve cells communicate with each other.

David Holtzman, M.D., and colleagues have developed a method to assess the levels of beta-amyloid in interstitial fluid (ISF), the fluid surrounding brain cells, in living, awake mice. These genetically altered mice carry a human Alzheimer-related gene and develop beta-amyloid aggregations.

In order to determine whether and how neural activity controls beta-amyloid levels in the brain, the researchers will use drugs and electrical stimulation to decrease or increase neural activity and monitor subsequent alterations in beta-amyloid concentrations. They will also examine whether artificial regulation of the brain's chemical messengers induces a similar change in amyloid concentrations. This work may clarify unknown factors about beta-amyloid pathology and suggest new lines of investigation for therapies.